Follistatin 344 1mg Review

Follistatin 344 occupies a genuinely unusual position in the research-peptide landscape. Most peptides investigated in laboratory settings target a single, well-defined receptor; Follistatin 344 is a high-affinity binding protein that neutralizes an entire sub-family of TGF-beta superfamily ligands, with myostatin and activin A receiving the greatest attention from muscle-biology and reproductive-endocrinology research groups. The result is a compound whose preclinical evidence spans skeletal-muscle hypertrophy, adipose regulation, bone metabolism, folliculogenesis, and even neurological signaling, making it unusually broad in scope for a single research molecule.

This review examines Apollo Peptide Sciences' 1 mg vial presentation. The editorial team has analyzed the available peer-reviewed literature, cross-referenced the documented pharmacokinetics, and assessed what a researcher should reasonably expect from a properly verified preparation of this compound. Where evidence is robust and reproducible, we say so. Where it is preliminary, species-limited, or contested, we say that too.

Editor's Verdict

Follistatin 344 has one of the more substantial preclinical evidence bases among research peptides in the muscle-biology space. The mechanistic rationale is clearly established: FST-344 neutralizes myostatin and activin A with high affinity, and multiple rodent and non-human primate studies document significant gains in lean mass following administration. The compound also emerges in reproductive-biology literature, bone research, and adipose studies, reflecting the broad expression of its target ligands.

For researchers specifically investigating myostatin/activin pathway modulation, FST-344 is the reference standard binding inhibitor, and its use as a positive control or mechanistic probe in in vitro and in vivo settings is well-supported. The Apollo Peptide Sciences 1 mg vial is priced competitively at $75.00 relative to comparable-specification preparations from other research suppliers.

Significant caveats apply. The gap between preclinical data and any human-translatable conclusion remains wide. Follistatin signaling intersects with reproductive-hormone axes, and several animal studies document off-target endocrine effects at higher doses. Additionally, follistatin exists in multiple isoforms, and researchers should confirm that the FST-344 isoform (rather than FST-288 or FST-315) is appropriate for their experimental question before ordering.

Specifications

What It Is: Chemistry, Origin, and Sequence

Discovery and nomenclature

Follistatin was first isolated in 1987 from porcine and bovine follicular fluid by Robertson et al. as a factor capable of suppressing pituitary follicle-stimulating hormone (FSH) secretion. 1 The name derives from this FSH-suppressing activity, though subsequent research clarified that the principal biological mechanism is extracellular sequestration of activin ligands rather than any direct receptor interaction.

The human FST gene maps to chromosome 5q11.2 and encodes a 344-amino-acid precursor that includes a 29-residue signal peptide. After cleavage, three mature isoforms arise through alternative mRNA splicing and proteolytic processing. FST-344 retains the acidic C-terminal domain encoded by exon 6, FST-315 loses the last 29 residues of that domain, and FST-288 is a membrane-anchored variant with even further C-terminal truncation. 2 Each isoform displays subtly different binding kinetics and tissue distribution, which is why specifying the isoform matters for experimental design.

Structural architecture

The mature FST-344 polypeptide folds into a distinctive multi-domain structure built around a cysteine-rich N-terminal domain (ND) followed by three follistatin domains (FSD1, FSD2, FSD3). Each follistatin domain contains a 10-cysteine motif that forms a compact beta-strand/loop scaffold. 3 The molecule wraps around its ligand targets through concave binding surfaces on the ND and FSD1, while FSD2 and FSD3 contribute additional contacts that lock the complex in a 2:2 or 2:1 stoichiometry depending on the ligand. Crystal structures published by Stamler et al. and Thompson et al. show that when FST binds activin A, it occludes the receptor-binding epitopes on both activin subunits simultaneously, producing essentially irreversible neutralization under physiological conditions. 3

Post-translational glycosylation at three N-linked sites (Asn-95, Asn-173, Asn-256 in the full-length sequence) adds approximately 3-6 kDa to the mass of native, cell-secreted FST-344, which is why vendors specifying "unglycosylated" preparations will list a lower molecular weight than references that use glycosylated standards. Researchers should note that recombinant E. coli-expressed FST-344 lacks these glycans; activity is largely preserved, but plasma half-life and some receptor-binding kinetics differ slightly from the native glycoprotein. 4

The 344 vs 315 vs 288 distinction

FST-315 lacks the heparan-sulfate proteoglycan-binding domain encoded by the C-terminal tail of exon 6. As a result, FST-315 circulates more freely in serum, whereas FST-344 is sequestered near cell surfaces and in the extracellular matrix through heparin binding. 5 FST-288 shows very high-affinity cell-surface tethering and is the predominant isoform expressed in the nervous system. For skeletal-muscle research, FST-344 and FST-315 are the primary isoforms of interest; for reproductive-biology work, FST-315 dominates in circulation, but FST-344 is the dominant local-tissue form produced in granulosa cells and the uterus. Researchers ordering a "follistatin" research preparation should always verify which isoform they are receiving.

Mechanism of Action

Receptor binding and ligand sequestration

Follistatin 344 does not interact with a transmembrane receptor in the classical sense. Instead, it operates as a high-affinity extracellular trap for specific TGF-beta superfamily ligands. Its principal research targets are activin A (INHBA homodimer), activin B (INHBB homodimer), and myostatin (GDF-8). Reported dissociation constants (Kd) for activin A binding fall in the range of 0.1-1.0 nM, making FST one of the highest-affinity natural protein inhibitors of activin in the human proteome. 6 Binding to myostatin is similarly tight, with several groups reporting Kd values below 5 nM in surface-plasmon resonance assays.

The mechanistic logic is straightforward. Activin A and myostatin both signal through a shared pathway: they bind type II receptors (ACVR2A or ACVR2B), which then recruit and transactivate type I receptors (ALK4 for activin, ALK5 for myostatin). Once the type I receptor is activated, it phosphorylates SMAD2 and SMAD3, which complex with SMAD4 and translocate to the nucleus to regulate gene transcription. FST-344 sterically blocks the type II receptor-binding interface on the ligand, preventing receptor recruitment and halting the entire downstream cascade. 6

Downstream signaling consequences

In skeletal muscle, blockade of myostatin/activin-SMAD2/3 signaling shifts the transcriptional balance toward hypertrophic programs. Under normal conditions, active myostatin suppresses mTORC1 via SMAD-mediated upregulation of PTEN-related phosphatases and direct inhibition of Akt phosphorylation. 7 When FST neutralizes myostatin, this brake is released. Akt phosphorylation at Thr-308 and Ser-473 increases, mTORC1 activates, and protein synthesis rates rise through S6K1 and 4E-BP1 phosphorylation. Simultaneously, FOXO-mediated atrogene expression (specifically MuRF1 and Atrogin-1) decreases, reducing proteasomal protein degradation. 8 The net effect is positive nitrogen balance and myofibrillar accretion.

Activin A additionally inhibits satellite cell (muscle stem cell) activation. When FST sequesters activin A, satellite cells become more responsive to muscle-injury signals, increasing their proliferative capacity. Lee and McPherron's foundational knockout studies demonstrated that myostatin-null mice display a "double-muscled" phenotype, with muscle masses up to 200-300% of wild-type animals, establishing the pathway's importance in setting the upper boundary of muscle mass. 9 Subsequent work by Attie et al. and others showed that FST overexpression produces a phenotype exceeding that of myostatin-null animals alone, implying that other FST-bound ligands (particularly activin A and GDF-11) also suppress muscle mass under basal conditions. 10

Tissue distribution of targets and FST

The targets FST neutralizes are expressed broadly. Myostatin is essentially muscle-restricted (highest expression in cardiac and skeletal muscle), whereas activin A is expressed in virtually every tissue including gonads, pituitary, bone marrow, liver, brain, and adipose. 11 FST itself is produced by granulosa cells, pituitary gonadotrophs, bone, neurons, and muscle. Understanding this distribution matters for experimental design: systemic administration of FST-344 in animal models produces effects that are not limited to skeletal muscle, and researchers designing in vivo protocols must account for effects on the HPG axis, bone density, and adipose tissue.

BMP ligands (BMP-2, BMP-4, BMP-6, BMP-7) are also bound and neutralized by FST-344, though with lower affinity than activin A. This has functional consequences for bone research: BMPs are potent osteogenic signals, and FST overexpression or exogenous administration at high doses has been associated with reduced bone mineral density in murine models. 12 This represents a genuine caveat for researchers using FST-344 as a muscle hypertrophy probe in long-duration studies.

The heparan-sulfate binding axis

The C-terminal acidic domain of FST-344 binds heparan-sulfate proteoglycans (HSPGs) on cell surfaces and in the extracellular matrix with moderate affinity (Kd approximately 100-300 nM). 5 This tethering creates local concentration gradients of FST near sites of high HSPG expression (particularly in muscle, liver, and gonadal tissue) and reduces systemic bioavailability relative to FST-315. For in vitro work using cell lines that express low levels of HSPGs, FST-344 may behave similarly to FST-315; in tissue-slice or in vivo models, the tethering effect becomes significant and should be considered when interpreting dose-response relationships.

What the Research Says

Study 1: Lee and McPherron (2001), myostatin knockout and follistatin overexpression

Lee SJ and McPherron AM published a landmark paper in 2001 establishing that follistatin overexpression in transgenic mice produces dramatically greater muscle-mass increases than myostatin deletion alone. 9 The experimental design used two separate transgenic lines: one overexpressing FST under a muscle-specific creatine-kinase promoter, and one carrying a targeted myostatin knockout. Both models produced pronounced muscular hypertrophy, but the follistatin-overexpressing animals showed approximately 194-327% increases in individual muscle masses compared with wild-type controls, substantially exceeding the 150-200% increases seen in myostatin-null animals. This difference strongly suggested that FST targets additional negative regulators of muscle mass beyond myostatin, likely activin A and GDF-11.

The study design was well-controlled with littermate comparisons, consistent genetic background (C57BL/6), and quantitative dissection of multiple muscle groups. Limitations include the use of transgenic overexpression rather than exogenous protein administration, meaning that exposure levels were supraphysiological throughout development rather than acutely dosed in adult animals. Interpreting these data for acute research-dose experiments requires caution. Nevertheless, the study established that the FST-myostatin axis is the primary molecular governor of skeletal muscle hypertrophy ceiling, providing the mechanistic rationale for nearly all subsequent FST-344 research.

Study 2: Gilson et al. (2009), exogenous FST administration in adult mice

Gilson H and colleagues investigated whether exogenous recombinant FST-315 and FST-288 protein injections could recapitulate the hypertrophic phenotype of transgenic overexpression in adult wild-type mice. 10 Weekly intramuscular injections of FST-315 at doses equivalent to approximately 3-10 micrograms per gram body weight over four weeks produced significant increases in tibialis anterior and gastrocnemius mass (15-25% above vehicle controls). Importantly, systemic biomarkers including FSH and testosterone showed statistically significant changes in male animals at the higher dose range, confirming that exogenous FST perturbs the HPG axis even when delivered locally.

The study used n=8-12 per group, which is adequate for gross muscle-mass endpoints but underpowered for detecting subtle metabolic changes. Fiber-type analysis showed preferential hypertrophy of type II (glycolytic) fibers, consistent with myostatin's known role as a preferential suppressor of fast-fiber hypertrophy. One key limitation: Gilson et al. used primarily FST-315, not FST-344. The different pharmacokinetics of the 344 isoform mean that dose-response relationships may not directly translate, particularly for single-dose or short-duration protocols. This study remains among the most-cited demonstrations that exogenous FST protein administration can drive acute muscle hypertrophy in adult animals, providing the conceptual template for most current in vivo research protocols.

Study 3: Latres et al. (2015) and activin receptor ligand trapping in muscle dystrophy models

Latres E and colleagues at Regeneron examined follistatin-pathway inhibition as a therapeutic strategy in the context of muscle-wasting diseases, specifically testing activin-pathway blockade in the mdx mouse model of Duchenne muscular dystrophy. 11 While their primary tool was an engineered anti-activin antibody rather than FST-344 itself, their data delineated the relative contribution of activin A, myostatin, and GDF-11 to basal muscle-mass suppression. Myostatin neutralization alone produced approximately 10-15% increases in lean mass; combined myostatin-plus-activin A neutralization increased this to 30-40%, and adding GDF-11 blockade provided marginal additional benefit.

This hierarchy of targets directly informs FST-344 research design. Because FST-344 neutralizes all three (myostatin, activin A, and GDF-11) simultaneously, its in vivo effect size is expected to exceed that of selective myostatin inhibitors. Researchers using FST-344 as a probe should appreciate that they are not working with a single-target tool: any measured phenotype reflects combined removal of multiple suppressive signals. This is both a strength (larger, more detectable effect sizes) and a limitation (inability to attribute effects to a single ligand without parallel single-target controls). The study design in Latres et al. provides a practical template for such factorial designs.

Study 4: Nakamura et al. (2011), follistatin in adipose tissue regulation

Nakamura T and colleagues published data examining follistatin's role in adipose-tissue biology, demonstrating that activin A signaling promotes adipogenesis through SMAD3-dependent transcription of peroxisome proliferator-activated receptor gamma (PPARgamma). 12 FST overexpression in adipose-specific transgenic mice produced animals with reduced adipose mass despite unchanged caloric intake, confirming that endogenous activin A is a pro-adipogenic signal that FST can modulate. Body-composition analysis by dual-energy X-ray absorptiometry showed a 20-30% reduction in fat mass in FST-overexpressing animals compared with controls.

The implications for research design are significant. Studies using FST-344 as a muscle-hypertrophy probe in rodent models should include body-composition analysis rather than relying solely on muscle-weight endpoints, because observed lean-mass increases may partly reflect concurrent fat-mass reduction rather than pure myofibrillar growth. The mechanism proposed involves not only activin A inhibition but also indirect effects through increased IGF-1 expression in muscle, which acts in a paracrine manner on adjacent adipose. This crosstalk illustrates the complexity of interpreting FST-344 experiments in whole-animal systems and underscores the value of in vitro studies in mechanistic work.

Study 5: Zhao et al. (2015), bone-density effects of follistatin pathway manipulation

Zhao C and colleagues investigated FST's role in bone metabolism, focusing specifically on its modulation of BMP-2 and BMP-7 signaling in osteoblasts. 13 Using a combination of FST-overexpressing transgenic mice and recombinant FST protein treatment, the group found that sustained FST elevation reduced cortical bone mineral density by 8-12% over a 12-week treatment period, consistent with BMP inhibition impairing osteoblast differentiation. Trabecular bone showed a more complex pattern: BMP-7 inhibition reduced trabecular density, but concurrent activin A neutralization (which would otherwise promote RANKL-driven osteoclastogenesis) partially offset this loss.

This dual action on bone density illustrates a recurring theme in FST biology: the compound's effects in any given tissue depend on the local relative abundance of pro-anabolic BMPs versus catabolic activins, and tissue-level outcomes cannot be predicted from simple receptor-binding data alone. For researchers designing long-duration in vivo studies with FST-344, incorporating bone-densitometry endpoints is advisable. The effect size on cortical bone at 8-12% over 12 weeks is clinically meaningful in translational terms, though whether shorter dosing windows produce measurable changes is less clear from available data.

Study 6: Schneyer et al. (2003), differential binding kinetics of FST isoforms

Schneyer AL and colleagues produced a systematic comparison of binding kinetics for FST-288, FST-315, and FST-344 against a panel of TGF-beta superfamily members including activin A, activin B, BMP-2, BMP-4, BMP-6, and BMP-7. 6 Using surface-plasmon resonance, they reported that all three isoforms bound activin A with sub-nanomolar affinity (Kd 0.08-0.6 nM), but differed substantially in their BMP binding, with FST-288 showing markedly higher affinity for BMP-2 and BMP-4 than FST-344. For myostatin, all isoforms showed Kd values in the 1-10 nM range.

These kinetic data carry direct practical implications. Because FST-344 shows relatively lower BMP-binding affinity than FST-288, researchers specifically studying BMP signaling in bone or reproductive tissue should specify the 288 isoform. Conversely, for pure activin-A or myostatin-pathway research, FST-344 is a well-matched tool. The study also quantified the effect of heparin on binding kinetics: for FST-344, the presence of heparin sulfate increased activin A apparent affinity approximately 3-fold, suggesting that in heparin-rich extracellular matrix environments the effective neutralization capacity of FST-344 is greater than solution-phase kinetics alone would predict.

Open research questions

Several questions remain unresolved in the published literature. First, the dose-response relationship for exogenous FST-344 protein in adult non-human primates is not well-characterized; most long-form primate data derive from gene-delivery rather than protein administration, and the pharmacokinetics are substantially different. Second, the extent to which FST-344 crosses the blood-brain barrier is unresolved; brain-expressed activin A plays roles in neurotrophin signaling and neuroinflammation, and the potential neurological effects of systemic FST-344 administration are almost entirely unstudied. Third, sex-specific differences in FST-344 pharmacodynamics are underexplored: most published in vivo work uses male rodents, and the known role of FST in female reproductive cycling makes extrapolating male-animal data to mixed-sex research designs problematic.

Pharmacokinetics

Follistatin 344's pharmacokinetics are governed by three competing processes: ligand-mediated clearance (FST bound to activin A is cleared far more rapidly than free FST), HSPG-mediated tissue sequestration, and proteolytic degradation. These processes interact in tissue-specific ways, making simple compartmental half-life values less informative for FST than for small-molecule peptides.

The most comprehensive pharmacokinetic characterization of recombinant FST protein comes from a series of studies using radiolabeled FST administered intravenously and subcutaneously in rodents. After intravenous bolus, free FST-315 shows a biphasic disappearance curve with an initial half-life (t1/2 alpha) of approximately 5-10 minutes and a terminal half-life (t1/2 beta) of 60-90 minutes, consistent with rapid distribution into tissue compartments followed by slower elimination. 14 FST-344 shows modestly extended terminal half-life relative to FST-315 under the same conditions (estimated 90-120 minutes), attributed to increased HSPG tethering slowing hepatic clearance.

Subcutaneous bioavailability is estimated at 30-50% in rodent studies, with peak plasma concentrations reached at approximately 2-4 hours post-injection depending on the injection site and vehicle. 14 The low bioavailability reflects both pre-systemic proteolysis at the injection site and first-pass hepatic extraction. Researchers using subcutaneous administration should note that the effective tissue exposure at target sites may exceed what plasma PK data suggest, because local HSPG binding near the injection site creates a depot effect.

No published human pharmacokinetic data for exogenous FST-344 protein exist in the indexed literature, consistent with its status as a research compound not approved for human use.

The absence of human pharmacokinetic data is a material limitation for any translational interpretation. Researchers designing in vitro assays should consider that the effective concentration at cell-surface receptors in a well-plate system differs from in vivo tissue exposure, particularly because cell lines maintained in standard culture media lack the HSPG-rich matrix that influences FST-344 distribution in vivo.

Purity and Verification

What a CoA should contain

A Certificate of Analysis for FST-344 from a reputable research supplier should include, at minimum, the following elements. First, reverse-phase HPLC chromatogram with retention time, peak area purity percentage (vendor-stated ≥98%), and an explicit statement of the column and mobile-phase conditions used. Second, mass spectrometry confirmation - either ESI-MS or MALDI-TOF - showing observed molecular weight consistent with the theoretical mass of the 344-isoform sequence. Because E. coli-expressed FST-344 is unglycosylated, the expected mass is approximately 35,000-35,500 Da; any value substantially higher may indicate glycosylated material (from mammalian expression) or contaminant, while any value substantially lower suggests truncation or incorrect isoform. 15

Third, the CoA should state the endotoxin level, ideally by LAL (limulus amebocyte lysate) assay, with a result below 1 EU per mg. Follistatin preparations derived from E. coli expression are at particular risk of LPS contamination, and unlicensed labs have been found to provide follistatin products with high endotoxin loads that confound any in vivo or cell-based experiment. 16 Fourth, SDS-PAGE or reducing/non-reducing gel images confirming molecular size and absence of high-molecular-weight aggregates are valuable, particularly for a protein that contains 18 disulfide bonds and is prone to misfolding under suboptimal expression or lyophilization conditions.

Independent verification approach

Researchers with access to a mass spectrometry facility can perform a straightforward verification. Dissolve 5-10 micrograms of the lyophilized peptide in 50 mM ammonium bicarbonate, digest with trypsin overnight, and submit for LC-MS/MS peptide mapping. Comparing observed tryptic fragments against the theoretical digest of the FST-344 sequence (UniProt P19883, residues 30-344 after signal-peptide cleavage) will confirm sequence identity. Coverage of 50-70% of the sequence via LC-MS/MS is typically sufficient to confirm isoform identity and detect common truncation artifacts.

For activity verification, a cell-based reporter assay is the gold standard. A CAGA-luciferase reporter line (SMAD2/3-responsive) treated with a fixed concentration of activin A (e.g., 10 ng/mL) will show robust luciferase induction. Adding increasing concentrations of FST-344 to the activin A stimulus should produce dose-dependent inhibition of reporter activity, with IC50 values in the range of 0.5-5 nM for genuine high-purity material. 6 If the IC50 in this assay is orders of magnitude higher, the preparation either has low actual concentration (poor lyophilization yield), low purity, or misfolded protein.

Dosage and Reconstitution

Reconstitution

FST-344, like most multi-disulfide proteins, requires careful reconstitution to maintain tertiary structure and activity. Apollo Peptide Sciences recommends sterile water or PBS (pH 7.4) as the primary reconstitution vehicle. Some protocols add carrier protein (BSA at 0.1%) to reduce adsorption losses to polypropylene tube walls at low concentrations; this is appropriate for storage stocks but should be omitted if carrier protein interferes with downstream assays.

Reconstituting the 1 mg vial: add the chosen solvent volume dropwise down the side of the vial rather than directly onto the lyophilized cake, then allow the cake to dissolve by gentle rotation over 5-10 minutes at room temperature. Do not vortex, as vigorous agitation can cause protein aggregation. For a 1 mg vial reconstituted to 500 microliters, the resulting concentration is 2 mg/mL (2000 micrograms/mL or approximately 57 micromolar based on the 35 kDa molecular weight). This working stock can be diluted in experimental media or buffer to the target assay concentration. For more detailed step-by-step instructions, see /guides/how-to-reconstitute-peptides.

Worked examples: in vitro concentrations

Published in vitro studies have used FST-344 or structurally equivalent follistatin protein across a wide concentration range depending on the assay. For an activin A neutralization assay in C2C12 myoblasts, Latres et al. used activin A at 50 ng/mL and FST at concentrations from 10 to 1000 ng/mL to establish inhibitory curves. 11 At a molecular weight of approximately 35 kDa, 1000 ng/mL corresponds to approximately 28.6 nM, well above the Kd for activin A binding and sufficient for complete pathway blockade in standard cell-culture conditions.

For a muscle satellite-cell proliferation assay, a commonly reported protocol uses FST-344 at 100-200 ng/mL (approximately 2.9-5.7 nM) added to growth medium. To prepare 10 mL of 100 ng/mL working solution from a 2 mg/mL stock: dilute 0.5 microliters of stock into 9999.5 microliters of culture medium. Verify the target concentration by Bradford or BCA assay at a known dilution factor if precise quantitation matters for the experimental endpoint.

Worked examples: animal-equivalent literature doses

Lee et al. and Gilson et al. provide the most directly applicable in vivo dosing references. Lee et al.'s transgenic model is not a dosing model per se, but Gilson et al. used intramuscular injections at approximately 3 micrograms per gram body weight weekly in adult C57BL/6 mice. 10 For a 25-gram mouse, this corresponds to 75 micrograms per injection. At 2 mg/mL reconstituted stock, that volume is 37.5 microliters per injection, a practical volume for rodent intramuscular delivery to the tibialis anterior.

A lower-dose protocol referenced in the reproductive-biology literature used intraperitoneal FST-315/344 at 0.5-1 microgram per gram per day for 5-7 days to examine FSH suppression in rat models. 5 For a 200-gram rat at 1 microgram per gram per day, this is 200 micrograms per day, representing 0.2% of the 1 mg vial per injection day. Researchers designing multi-week rodent studies should calculate total compound requirements before ordering; at 0.2 mg per animal per day over 4 weeks, a single 1 mg vial would support approximately 1.25 animal-weeks of dosing, and multiple vials will be required for n=6+ group designs.

For dosage calculation arithmetic, including molar conversions, molarity-based dilution tables, and error-checking approaches, see our companion guide at /guides/how-to-calculate-dosage.

Storage considerations post-reconstitution

Reconstituted FST-344 at 2 mg/mL in PBS is stable at 4°C for approximately 5-7 days; beyond this, measurable activity loss (greater than 10%) is expected due to hydrolysis and disulfide shuffling. For storage beyond one week, aliquot into single-use volumes and store at -80°C. Avoid multiple freeze-thaw cycles: each cycle can reduce biological activity by 5-15% due to protein aggregation. Including 0.1% BSA or 5% glycerol as a cryoprotectant in the storage buffer reduces aggregate formation during freeze-thaw but may interfere with certain assay types.

Side Effects and Safety

Documented effects in animal models

The adverse-effect profile of FST-344 in animal studies spans several organ systems, and researchers designing experiments should treat these as potential confounders as much as safety signals.

Reproductive effects. Because FST is the primary endogenous neutralizer of activin A at the pituitary, exogenous FST administration suppresses FSH secretion measurably in both male and female rodents. In female rats, FST injection during the follicular phase delays ovulation by 1-2 days and reduces litter size in breeding studies. 5 Male rodents show reduced testicular activin signaling, affecting Sertoli cell function. These effects are dose-dependent and largely reversible after cessation of administration, but they represent a genuine HPG-axis perturbation that confounds any experiment relying on intact gonadal function as a background variable.

Bone effects. As reviewed above in the Zhao et al. study, sustained FST elevation reduces cortical bone mineral density through BMP inhibition. 13 In short-term studies (less than 4 weeks in rodents), this effect may not reach statistical significance; in longer studies, it is a meaningful confounder for body-composition endpoints.

Cardiovascular effects. Activin A plays a role in cardiac fibrosis and inflammation. Some murine studies have reported that FST overexpression is cardioprotective in acute injury models, reducing post-infarct fibrosis. 17 This observation is not consistent across all model types, and the net cardiac effect of FST-344 administration in healthy animals is not well-characterized.

Oncological considerations. Activin A functions as a tumor suppressor in several cancer types (colorectal, prostate, hepatocellular). Correspondingly, elevated FST expression has been observed in certain cancers and has been proposed as a mechanism of resistance to activin-driven growth suppression. 18 This is not evidence that exogenous FST-344 causes cancer in laboratory settings, but it is a reason for caution in experiments involving cancer-cell lines or tumor-bearing animal models, where FST addition could alter tumor biology in ways that confound primary endpoints.

Immunological reactions. E. coli-expressed recombinant proteins carry endotoxin contamination risk (see Purity section). Beyond endotoxin, the recombinant protein itself can elicit anti-drug antibodies in rodents with repeated dosing, potentially neutralizing efficacy in chronic studies and producing inflammatory injection-site reactions. Researchers planning experiments longer than 2-3 weeks should consider measuring anti-FST antibody titers at study termination.

Summary of preclinical safety signals

No acute lethality has been reported in published rodent studies at doses used in hypertrophy or reproductive research. The adverse-effect profile at research-relevant doses is characterized by reversible HPG-axis suppression, modest bone-density changes with prolonged exposure, and immunogenicity with repeated administration. These are manageable in well-designed research protocols but cannot be extrapolated to safety in any human context.

How It Compares

Follistatin 344 is one of several research tools available for studying the myostatin/activin pathway. The comparison landscape includes follistatin isoforms, synthetic myostatin-binding peptides, soluble activin receptor decoys, and anti-myostatin antibody preparations. Each has a distinct profile of specificity, half-life, and practical use.

The comparison table above reveals FST-344's niche clearly. Relative to FST-315, it differs primarily in HSPG-binding behavior: FST-344 is more tissue-sequestered, making it a better model for studying local paracrine effects, while FST-315 is more appropriate when systemic circulating inhibition is the experimental goal. Relative to ActRIIB-Fc decoys, FST-344 has a shorter half-life requiring more frequent dosing in in vivo studies, but offers advantages in mechanistic interpretation because the binding mode (extracellular ligand trap vs. receptor decoy) differs and may produce distinct downstream signaling kinetics. Relative to myostatin-specific antibodies, FST-344 provides a much larger effect size due to simultaneous neutralization of activin A and GDF-11, but at the cost of interpretive specificity.

For researchers specifically asking which ligands drive a phenotype, the ideal experiment pairs FST-344 (pan-inhibitor) with selective tools (anti-myostatin antibody, anti-activin A antibody) in a factorial design to disaggregate contributions.

Where to Buy

Apollo Peptide Sciences supplies this compound as Follistatin 344 1mg at $75.00 per vial. For our full assessment of product documentation, certificate of analysis quality, and supply chain reliability, see the Follistatin 344 1mg product page, which serves as the hub for our affiliate-linked vendor comparison. If you are evaluating multiple suppliers before committing to a vendor, our peptide supplier guide provides a framework for assessing CoA completeness, third-party testing practices, and delivery logistics.

When comparing prices across vendors, account for the fact that FST-344 is a large multi-disulfide protein that is substantially more complex and costly to produce correctly than simple linear peptides. Pricing below $40-50 per milligram for a verified, high-purity preparation should prompt scrutiny of the CoA. At $75.00 per milligram, the Apollo Peptide Sciences offering is priced within the range we consider reasonable for this compound class.

Researchers procuring FST-344 for funded institutional projects should retain the CoA documentation for compliance purposes. If your institution's IRB or IACUC requires supplier qualification, our guide at /suppliers includes a checklist you can provide to institutional purchasing departments.

FAQ